Full name
A Phase 2a, Single Dose, Open-label, Dose Exploration Study to Assess the PK-PD Activity, Safety, and Tolerability of GSK4532990 in Adult Participants With NASH or Suspected NASH
NCT Number
NCT06104319
Geography
US
Locations
United States
Primary Endpoints
- Predicted percent change from baseline in liver biopsy-derived HSD17B13 protein expression levels. Baseline (Day 1) and up to Week 28
- Predicted percent change from baseline in liver biopsy-derived HSD17B13 mRNA expression levels. Baseline (Day 1) and up to Week 28
Order
2
Disease
Version
Phase
2a
Status
Recruiting